Chennai, India — Authorities have taken the owner of a pharmaceutical company into custody in connection with a cough syrup that has been linked to the tragic deaths of at least 21 children in Madhya Pradesh. The young victims, all under the age of five, passed away in recent weeks after being prescribed the contaminated syrup.
G. Ranganathan, 75, was arrested early Thursday morning at his residence in Chennai. Police charged him with culpable homicide not amounting to murder and adulteration of drugs, following investigations into the incident. The cough syrup, marketed as Coldrif, was produced by Sresan Pharma, based in Tamil Nadu. The Indian health ministry confirmed that laboratory tests found the syrup contained diethylene glycol (DEG), a toxic substance that can be deadly even in minimal doses.
In response to the alarming findings, Madhya Pradesh and several other states have initiated bans on the product, underscoring ongoing concerns about the safety of pharmaceutical products in India. The situation has drawn international attention, with the World Health Organization seeking explanations from Indian health officials regarding the possibility of the toxic syrup being exported abroad.
The rise in incidents involving harmful cough syrups produced in India is not new. In 2022, over 70 children in The Gambia died from acute kidney failure linked to a cough syrup imported from India. This year’s reports indicate that at least 68 children in Uzbekistan experienced similar fates due to a different contaminated product from the country. As these cases unfold, global health agencies are collaborating to investigate the sources of these dangerous medications.
India, a major player in the global pharmaceutical industry, reportedly ranks as the third-largest drug producer by volume, trailing only behind the United States and China. However, the recent string of incidents has severely impacted its reputation. The issue raises significant concerns about regulatory oversight within the pharmaceutical sector and the potential risks to public health when stringent safety measures are not maintained.
The case has sparked outrage among families and advocacy groups, who are demanding accountability and stricter regulations to ensure children’s safety. “This is a heartbreaking tragedy that should never have happened,” expressed a local health advocate. “Children are vulnerable, and it’s our responsibility to protect them from harmful substances.”
As investigations continue, the Indian government faces mounting pressure to improve safety practices within its pharmaceutical manufacturing processes. The community is hoping for swift justice while seeking assurance that no such incident will occur in the future, emphasizing the need for thorough quality control and transparency in drug production.